Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Hepatocellular carcinoma
(
HCC
) possesses high morbidity and mortality and has become the most frequently diagnosed liver cancer globally. Long noncoding RNAs have been widely studied because they exert essential functions in human diseases.
Aim of the Study:
The aim of the study is to explore the role and molecular regulatory mechanism of
TRIM52-AS1
in
HCC
.
Materials and Methods:
Real-time quantitative polymerase chain reaction examined
TRIM52-AS1
,
miR-514a-5p
, and mitochondrial ribosomal protein S18a (
MRPS18A
) expression in
HCC
cells. Cell Counting Kit-8 (CCK-8), colony formation, flow cytometry, JC-1, transwell, and western blot assays uncovered the function of
TRIM52-AS1
in
HCC
. RNA immunoprecipitation (RIP), RNA pull down, and luciferase reporter assays validated the association among
TRIM52-AS1
,
miR-514a-5p
, and
MRPS18A
. Nuclear-cytoplasmic fractionation assay revealed the subcellular location of
TRIM52-AS1
in
HCC
cells.
Results:
TRIM52-AS1
was revealed to be upregulated in
HCC
tissue samples according to GEPIA database. Consistent results were recognized in
HCC
cell lines. Subsequently, loss-of-function assays confirmed that
TRIM52-AS1
ablation depressed cell proliferation, migration, invasion, and epithelial-to-mesenchymal transition process
in vitro
and inhibited tumor growth
in vivo
. Furthermore, the authors validated
TRIM52-AS1
bound with
miR-514a-5p
in
HCC
.
TRIM52-AS1
inversely regulated
miR-514a-5p
expression. Afterward,
MRPS18A
was identified to be a downstream target of
miR-514a-5p
. Ultimately, rescue assays manifested that
MRPS18A
upregulation could neutralize the attenuated effects resulting from
TRIM52-AS1
deficiency.
Conclusions:
All in all,
TRIM52-AS1
sponged
miR-514a-5p
to facilitate
HCC
progression through increasing
MRPS18A
expression. The findings highlight
TRIM52-AS1
as a novel therapeutic target for
HCC
.
...
PMID:Long Noncoding RNA
TRIM52-AS1
Sponges
miR-514a-5p
to Facilitate Hepatocellular Carcinoma Progression Through Increasing
MRPS18A
. 3239 16